André Goy

37.7k total citations · 2 hit papers
341 papers, 10.1k citations indexed

About

André Goy is a scholar working on Pathology and Forensic Medicine, Genetics and Oncology. According to data from OpenAlex, André Goy has authored 341 papers receiving a total of 10.1k indexed citations (citations by other indexed papers that have themselves been cited), including 222 papers in Pathology and Forensic Medicine, 144 papers in Genetics and 141 papers in Oncology. Recurrent topics in André Goy's work include Lymphoma Diagnosis and Treatment (220 papers), Chronic Lymphocytic Leukemia Research (134 papers) and CAR-T cell therapy research (55 papers). André Goy is often cited by papers focused on Lymphoma Diagnosis and Treatment (220 papers), Chronic Lymphocytic Leukemia Research (134 papers) and CAR-T cell therapy research (55 papers). André Goy collaborates with scholars based in United States, France and United Kingdom. André Goy's co-authors include Barbara Pro, Peter McLaughlin, K. Stephen Suh, Jorge Romaguera, Luis Fayad, Anas Younes, Owen A. O’Connor, Brad S. Kahl, Felipe Samaniego and Michael Wang and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

André Goy

321 papers receiving 9.8k citations

Hit Papers

Multicenter Phase II Stud... 2006 2026 2012 2019 2006 2011 100 200 300 400 500
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Multicenter Phase II Study of Bortezomib in Patients With Relapsed or Refractory Mantle Cell Lymphoma
    2006 553 citations Brad S. Kahl, Owen A. O’Connor et al. Journal of Clinical Oncology profile →
  2. Pralatrexate in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results From the Pivotal PROPEL Study
    2011 439 citations Owen A. O’Connor, Barbara Pro et al. Journal of Clinical Oncology profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
André Goy 6.1k 4.9k 3.0k 2.6k 1.5k 341 10.1k
Michael Crump 5.6k 0.9× 5.3k 1.1× 2.4k 0.8× 1.6k 0.6× 1.2k 0.8× 310 9.8k
Eric D. Hsi 6.0k 1.0× 4.7k 1.0× 3.5k 1.2× 3.2k 1.2× 2.6k 1.8× 405 12.2k
Michele Ghielmini 6.5k 1.1× 4.5k 0.9× 3.1k 1.0× 932 0.4× 1.5k 1.0× 134 8.8k
Jonathan W. Friedberg 9.1k 1.5× 6.5k 1.3× 3.8k 1.3× 1.5k 0.6× 1.9k 1.3× 393 12.7k
Catherine Thiéblemont 9.9k 1.6× 7.0k 1.4× 4.4k 1.5× 2.0k 0.8× 1.9k 1.3× 420 14.3k
Myron S. Czuczman 6.5k 1.1× 4.6k 0.9× 3.5k 1.2× 2.0k 0.8× 1.9k 1.3× 241 10.4k
Steven Le Gouill 3.7k 0.6× 3.3k 0.7× 1.7k 0.6× 2.1k 0.8× 1.2k 0.8× 312 7.2k
Stephen J. Schuster 4.7k 0.8× 8.3k 1.7× 2.0k 0.7× 1.7k 0.7× 2.9k 2.0× 366 11.7k
Thomas M. Grogan 3.4k 0.6× 5.0k 1.0× 1.4k 0.5× 3.1k 1.2× 1.2k 0.8× 160 9.2k
Franco Cavalli 7.7k 1.3× 5.0k 1.0× 2.7k 0.9× 1.5k 0.6× 902 0.6× 190 11.6k

Countries citing papers authored by André Goy

Since Specialization
Citations

This map shows the geographic impact of André Goy's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by André Goy with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites André Goy more than expected).

Fields of papers citing papers by André Goy

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by André Goy. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by André Goy. The network helps show where André Goy may publish in the future.

Co-authorship network of co-authors of André Goy

This figure shows the co-authorship network connecting the top 25 collaborators of André Goy. A scholar is included among the top collaborators of André Goy based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with André Goy. André Goy is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Rowley, Scott D., Maher Albitar, Alaa M. Ali, et al.. (2025). cfDNA Chimerism and Somatic Mutation Testing in Early Prediction of Relapse After Allogeneic Stem Cell Transplantation for Myeloid Malignancies. Cancers. 17(4). 625–625. 1 indexed citations
2.
Chu, Paul K., et al.. (2024). Bruton’s tyrosine kinase inhibitor associated localized extremity edema and erythema. JAAD Case Reports. 54. 93–97. 1 indexed citations
3.
Albitar, Maher, Andrew Ip, Sally Agersborg, et al.. (2024). Using cell-free RNA in monitoring immune system and the demonstration of significant systemic deficiency in lymphoid and myeloid biomarkers in patients with cancer.. Journal of Clinical Oncology. 42(16_suppl). 3048–3048. 1 indexed citations
4.
Feghali, Karine A. Al, Lydia Pascual, Michael Marafelias, et al.. (2023). Prevalence of Non-Hodgkin Lymphoma Patients at High Risk of Failure after CAR T-Cell Therapy Eligible for Bridging Radiation Therapy. International Journal of Radiation Oncology*Biology*Physics. 117(2). e463–e464.
5.
Ali, Alaa M., André Goy, & Kieron Dunleavy. (2022). CAR T-cell therapy in highly aggressive B-cell lymphoma: emerging biological and clinical insights. Blood. 140(13). 1461–1469. 13 indexed citations
6.
Cook, Michael, Kepher H. Makambi, Yutong Luo, et al.. (2022). Toxicity and efficacy of CAR T-cell therapy in primary and secondary CNS lymphoma: a meta-analysis of 128 patients. Blood Advances. 7(1). 32–39. 61 indexed citations
7.
Supko, Jeffrey G., Michael B. Maris, Ian W. Flinn, et al.. (2022). A Phase I Study of Pelabresib (CPI-0610), a Small-Molecule Inhibitor of BET Proteins, in Patients with Relapsed or Refractory Lymphoma. Cancer Research Communications. 2(8). 795–805. 23 indexed citations
8.
Matasar, Matthew J., Chan Y. Cheah, Dok Hyun Yoon, et al.. (2020). Subcutaneous Mosunetuzumab in Relapsed or Refractory B-Cell Lymphoma: Promising Safety and Encouraging Efficacy in Dose Escalation Cohorts. Blood. 136(Supplement 1). 45–46. 27 indexed citations
9.
Ip, Andrew, Anthony R. Mato, Nicholas P. Howard, et al.. (2020). COVID-19 Impact on Lymphoma Patients' Clinical Outcomes - an Observational Cohort Study. Blood. 136(Supplement 1). 6–7. 5 indexed citations
10.
Rule, Simon, Martin Dreyling, André Goy, et al.. (2019). Long-Term Outcomes with Ibrutinib Versus the Prior Regimen: A Pooled Analysis in Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL) with up to 7.5 Years of Extended Follow-up. Blood. 134(Supplement_1). 1538–1538. 16 indexed citations
11.
Rule, Simon, Martin Dreyling, André Goy, et al.. (2017). Median 3.5-Year Follow-up of Ibrutinib Treatment in Patients with Relapsed/Refractory Mantle Cell Lymphoma: A Pooled Analysis. Blood. 130. 151–151. 4 indexed citations
12.
Goy, André, Tatyana Feldman, Lori A. Leslie, et al.. (2017). Phase Ib-II Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib, w/ Lenalidomide and Rituximab in Relapsed / Refractory Mantle Cell Lymphoma. Blood. 130. 2785–2785. 1 indexed citations
13.
Advani, Ranjana H., Daniel Lebovic, Andy Chen, et al.. (2016). Phase I Study of the Anti-CD22 Antibody–Drug Conjugate Pinatuzumab Vedotin with/without Rituximab in Patients with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma. Clinical Cancer Research. 23(5). 1167–1176. 65 indexed citations
14.
Fraser, Graeme, Paula Cramer, Fatih Demırkan, et al.. (2016). IBRUTINIB PLUS BENDAMUSTINE AND RITUXIMAB IN PREVIOUSLY TREATED CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL/SLL): 2-YEAR FOLLOW-UP INCLUDING MRD FROM THE HELIOS STUDY. Haematologica. 101. 150–151. 4 indexed citations
15.
Howlett, Christina, Sonya J. Snedecor, Daniel J. Landsburg, et al.. (2015). Front‐line, dose‐escalated immunochemotherapy is associated with a significant progression‐free survival advantage in patients with double‐hit lymphomas: a systematic review and meta‐analysis. British Journal of Haematology. 170(4). 504–514. 113 indexed citations
16.
17.
Feldman, Tatyana, Kar Fai Chow, Anthony R. Mato, et al.. (2013). PEG-Asparaginase Based Multidrug Chemotherapy is Effective for Refractory Disseminated Extranodal NK/T-Cell Lymphoma With Leptomentigeal Involvement: A Clinical Case Report and Review of Literature. 2(1). 31–36. 1 indexed citations
18.
19.
Alsina, Melissa, Suzanne Trudel, Richard R. Furman, et al.. (2012). A Phase I Single-Agent Study of Twice-Weekly Consecutive-Day Dosing of the Proteasome Inhibitor Carfilzomib in Patients with Relapsed or Refractory Multiple Myeloma or Lymphoma. Clinical Cancer Research. 18(17). 4830–4840. 119 indexed citations
20.
O’Connor, Owen A., Barbara Pro, Lauren Pinter‐Brown, et al.. (2011). Pralatrexate in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results From the Pivotal PROPEL Study. Journal of Clinical Oncology. 29(9). 1182–1189. 439 indexed citations breakdown →

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Michael Crump Breakdown of academic impact, for papers by Eric D. Hsi Breakdown of academic impact, for papers by Michele Ghielmini Breakdown of academic impact, for papers by Jonathan W. Friedberg Breakdown of academic impact, for papers by Catherine Thiéblemont Breakdown of academic impact, for papers by Myron S. Czuczman Breakdown of academic impact, for papers by Steven Le Gouill Breakdown of academic impact, for papers by Stephen J. Schuster Breakdown of academic impact, for papers by Thomas M. Grogan Breakdown of academic impact, for papers by Franco Cavalli
Rankless by CCL
2026